Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FIGHT: A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 2 Preceded by Dose Finding in Phase 1

NCT03343301 is registered in ClinicalTrials.gov with Five Prime Therapeutics, Inc. as lead sponsor.

NCT NCT03343301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03343301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FIGHT: A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 2 Preceded by Dose Finding in Phase 1
Lead sponsor
Five Prime Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2017
Completion date
January 31, 2019
Enrollment
12 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, gastrointestinal cancer, gastrointestinal cancer metastatic